Partha Anbil and Satish Tadikonda explore the current state of AI agents in drug discovery, with a specific focus on clinical data harmonisation, the transition to autonomous laboratories, and the projected market growth that underscores this technological revolution. Introduction: The dawn of agentic AI Drug discovery is notoriously protracted, expensive, and fraught with high attrition rates. The […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!